# Semaglutide Research: Mechanism, the STEP/SELECT/FLOW Trials, and Frontier Findings > Semaglutide research, logged: how it works, what the STEP, SUSTAIN-6, SELECT, FLOW and SURMOUNT-5 trials measured, and the emerging alcohol-craving evidence. Cited. Read like committed run records — each finding logged to its study, newest directions first. ## Start here Semaglutide research now spans tens of thousands of trial participants and several frontiers. This page logs it in plain language, then in full. The core idea: semaglutide copies GLP-1, a hormone your gut releases after eating that lowers blood sugar and curbs appetite. The natural hormone lasts about two minutes; semaglutide is rebuilt to last about a week, so one dose works for seven days [12]. Big trials show large weight loss [1], lower heart-attack and stroke risk [3], and slower kidney decline in diabetes [6]. The newest line is about the brain's reward system — early evidence that it can reduce alcohol drinking [8]. Below: what it is, how it works, the landmark trials, how it compares to tirzepatide, and the frontier. ## What is semaglutide Semaglutide is a 31-amino-acid acylated analogue of human GLP-1, sharing about 94% of its sequence with the natural hormone [12]. Two changes make it last: a position-8 substitution (alpha-aminoisobutyric acid) blocks the enzyme DPP-4 that normally chews up GLP-1 in minutes, and a C18 fatty-acid side chain binds tightly but reversibly to albumin (the most abundant protein in blood), which shields the drug from rapid clearance [12]. The net effect is an elimination half-life of about one week, with effectively complete clearance roughly five weeks after the last dose [12]. It belongs to the GLP-1 receptor agonist class — drugs that switch on the GLP-1 receptor to mimic the natural incretin (a gut hormone that boosts insulin after meals). It is FDA-approved, available as a once-weekly subcutaneous injection and a once-daily oral tablet [11]. ## How does semaglutide work Three mechanisms run in parallel. First, glucose-dependent insulin secretion: it prompts the pancreas to release insulin only when blood glucose is high, which is why, on its own, it carries little hypoglycemia risk [12]. Second, it suppresses glucagon, the hormone that raises blood sugar [12]. Third, it slows gastric emptying, so food leaves the stomach more gradually [12]. The weight effect is largely central. A rodent study mapped how semaglutide reaches the brain directly — the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus — where it activates satiety neurons (POMC/CART) and inhibits hunger neurons (NPY/AgRP), cutting food intake and shifting food preference without lowering energy expenditure [4]. That same reward circuitry is the bridge to the alcohol research below. ## The landmark trials #### Semaglutide weight loss STEP 1 anchors the semaglutide weight loss record. Once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68 versus -2.4% on placebo in adults with overweight or obesity without diabetes (n=1,961) — a treatment difference of about 12.4 percentage points [1]. **Cardiovascular outcomes — SUSTAIN-6 and SELECT.** In SUSTAIN-6, semaglutide (0.5 or 1.0 mg weekly) reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.74; 95% CI 0.58-0.95) in type 2 diabetes at high cardiovascular risk; the same trial recorded more diabetic-retinopathy complications (HR 1.76; 95% CI 1.11-2.78) [2]. In SELECT (n=17,604), semaglutide 2.4 mg cut major adverse cardiovascular events by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001) in people with cardiovascular disease and obesity but no diabetes [3]. **Kidney outcomes — FLOW.** In type 2 diabetes with chronic kidney disease (n=3,533), semaglutide 1.0 mg weekly cut major kidney-disease events — kidney failure, a 50%-or-greater eGFR decline, or kidney/cardiovascular death — by 24% (HR 0.76; 95% CI 0.66-0.88) [6]. ## Semaglutide vs tirzepatide The most direct comparison is SURMOUNT-5, a head-to-head obesity trial (n=751). At 72 weeks, tirzepatide — a dual GIP/GLP-1 receptor agonist — produced greater mean weight loss than semaglutide: -20.2% versus -13.7%, an advantage of about 6.5 percentage points, statistically significant (P<0.001) [7]. The takeaway is comparative, not dismissive. Semaglutide's 13.7% in that trial is consistent with its own STEP-program record [1], and its separate cardiovascular- and kidney-outcome evidence stands on its own [3][6]. The two drugs act through overlapping but not identical receptor targets, which is the leading explanation for the weight-loss gap. ## The frontier: alcohol, reward, and body composition **Alcohol use disorder.** The headline emerging finding: in a phase-2 randomized trial (n=48), low-dose semaglutide reduced laboratory alcohol self-administration (grams consumed; beta -0.48, 95% CI -0.85 to -0.11, P=0.01) and predicted greater reductions in heavy drinking over nine weeks [8]. A rodent study found reduced alcohol intake and modulation of central GABA neurotransmission, supporting a reward-pathway mechanism [9], and a review of GLP-1 receptor agonists in alcohol use disorder reads the early evidence as promising while calling for larger trials [10]. Detail on the [semaglutide and alcohol](/alcohol) page. **Body composition.** A trial substudy reported that the weight lost includes both fat and a meaningful proportion of lean (muscle) mass — the basis for ongoing research into protein and resistance training to protect muscle [13]. Detail on the [semaglutide muscle loss](/muscle-loss) page. **Pharmacovigilance.** A real-world disproportionality analysis characterized the post-marketing adverse-event profile as dominated by gastrointestinal events, with additional signals under continued surveillance [18]. ## How to read this record Reproducibility is itself a finding. The weight effect repeats across the STEP program; the cardiovascular benefit appears in both diabetes (SUSTAIN-6) and non-diabetes (SELECT) populations [2][3]. The open questions are logged in plain view too: the alcohol work is early-phase and small [8], the lean-mass concern is an extrapolation from an observed substudy finding [13], and several safety signals remain unconfirmed [5]. Findings first, attribution after, gaps marked — not filled. --- A terminal-clean log of the semaglutide trial record — the STEP, SELECT, SUSTAIN-6 and FLOW figures committed to source, the emerging alcohol-craving lines flagged as early, and the unconfirmed signals left in plain view; no clinic behind the console, no script written, and nothing here dosed, compounded, or sold.